Introduction: The Hidden Threat of Advanced Kidney Cancer
Every year, hundreds of thousands of people around the world receive a life-altering diagnosis: kidney cancer. Among all subtypes of this disease, clear cell renal cell carcinoma (ccRCC) accounts for roughly 80% of all kidney cancer cases, and it carries unique challenges once it reaches an advanced stage. When kidney cancer advances, it falls into two difficult categories: unresectable disease, meaning surgeons cannot safely remove the entire tumor, and metastatic disease, meaning cancer cells have broken away from the kidney and spread to distant organs like the lungs, bones, liver, or brain.
For patients facing advanced clear cell kidney cancer, treatment options have improved dramatically over the past two decades—but many people still struggle with tumors that stop responding to single drugs, uncomfortable side effects that disrupt daily life, or slow tumor control that drags on for months or years. Doctors and researchers are constantly searching for gentler, more powerful treatment combinations that can shrink tumors longer, extend patients’ quality of life, and delay cancer progression without unbearable toxic reactions. Today, we will break down a brand-new clinical trial running out of Peking Union Medical College Hospital in Beijing, China, that tests a two-drug combination as a first-line treatment for newly diagnosed advanced kidney cancer. This trial pairs a novel immunotherapy injection called envafolimab with a daily targeted pill known as axitinib. Before diving into the trial itself, we will unpack the basics of advanced kidney cancer, how each of these two drugs works, and why combining them could be a game-changing approach for patients who have never received any prior cancer treatment.
This article avoids dense medical jargon wherever possible, translates clinical trial terminology into plain language, and focuses on what this research means for regular patients and their families—not just oncologists and lab scientists. We will briefly cover the trial’s design, who can join, what participants will experience, and what outcomes researchers hope to measure, while centering the core story: why immunotherapy plus targeted therapy stands out as a promising frontline strategy for late-stage kidney cancer.
What Is Advanced Clear Cell Renal Cell Carcinoma, and Why Is It Hard to Treat?
Your kidneys are two fist-sized organs tucked in the back of your abdomen, responsible for filtering waste, balancing fluids, and making critical hormones that control blood pressure and red blood cell production. Renal cell carcinoma (RCC) starts in the tiny filtering units of the kidney called renal tubules. The clear cell subtype gets its name from how cancer cells look under a microscope: they fill with fat and glycogen, appearing pale and transparent.
Early-stage kidney cancer rarely causes obvious symptoms. Most small kidney tumors are found accidentally during scans for unrelated health issues, like abdominal pain or routine checkups. By the time patients develop noticeable signs—persistent back pain, blood in urine, unexplained weight loss, constant fatigue, or swelling in the legs—the cancer has often grown beyond the kidney or spread to other parts of the body. This is the advanced stage of RCC.
Two major hurdles make advanced ccRCC difficult to manage:
- Tumors rely heavily on new blood vessel growth: Kidney cancer cells overproduce a signal protein called VEGF, which forces the body to build hundreds of tiny new blood vessels to feed the tumor. Without this blood supply, tumors cannot grow or spread. This unique trait makes targeted drugs that block VEGF signals highly relevant for RCC treatment.
- Kidney cancer hides from the human immune system: Cancer cells craft molecular “cloaks” to avoid detection by immune cells. One common cloak protein is PD-L1, which sits on the surface of tumor cells. When PD-L1 connects to a matching protein on immune cells called PD-1, it sends a “do not attack” signal that shuts down the body’s natural cancer-fighting defenses. Immunotherapies target this cloaking system to wake up dormant immune cells.
For decades, doctors relied on one single drug at a time for advanced kidney cancer. Some patients saw tumor shrinkage, but many developed drug resistance quickly—meaning the tumor stopped responding after months of treatment. Other patients dealt with severe side effects that forced them to pause or stop treatment entirely. Researchers hypothesized long ago that pairing two drugs with completely different mechanisms of action—one to cut off the tumor’s blood supply, one to unleash the immune system—could create a one-two punch stronger than either drug alone. The trial exists to test this exact hypothesis in patients who have not tried any prior systemic anti-cancer therapy.
Meet the Two Study Drugs: Envafolimab and Axitinib
This trial’s treatment arm combines two distinct anti-cancer medications, each with a separate, easy-to-understand function. We will break them down individually before explaining how they work better together.
Envafolimab: A Subcutaneous Immunotherapy That Takes Off Cancer’s Immune Cloak
Envafolimab is an immune checkpoint inhibitor, a class of drugs that revolutionized cancer care over the last 15 years. Unlike many older immunotherapies given through slow intravenous (IV) infusions in a hospital chair for hours, envafolimab is delivered via a simple under-the-skin (subcutaneous) injection, much like a flu shot. Patients receive a 400 mg dose once every three weeks.
To simplify its mechanism: imagine your immune cells as security guards patrolling your body to hunt and destroy abnormal cancer cells. Kidney cancer cells produce PD-L1, a protein that acts like a fake security pass. When immune guards spot this pass, they stand down and leave the tumor unharmed. Envafolimab binds tightly to PD-L1 on cancer cells, covering up the fake pass so immune cells can no longer be tricked. Once unmasked, the immune system recognizes the tumor as a threat and launches targeted attacks to kill cancer cells, shrink existing tumors, and hunt down tiny hidden metastatic cells floating in the bloodstream.
A major benefit of subcutaneous envafolimab is convenience. IV immunotherapies require repeated long hospital visits with IV line placement, while under-the-skin shots cut down treatment time dramatically, easing stress and scheduling burdens for patients with chronic fatigue or mobility limitations.
Axitinib: An Oral Targeted Pill That Starves Tumors of Blood Flow
Axitinib is a targeted therapy taken as an oral tablet, twice per day at a standard 5 mg dose. Its core job is blocking VEGF receptor proteins on blood vessel cells. Remember that kidney tumors depend on constant new blood vessel growth to survive and expand. Axitinib acts like a traffic barrier, stopping VEGF signaling from telling the body to build tumor-feeding blood vessels.
Without fresh blood carrying oxygen and nutrients, tumor cells cannot multiply, and existing lesions shrink or stabilize. Unlike broad chemotherapy, which kills rapidly dividing healthy and cancer cells alike, axitinib zeroes in specifically on the molecular pathway kidney cancer uses to grow blood vessels. This precision means it carries fewer widespread toxic effects than traditional chemo, though it still comes with manageable side effects researchers will monitor closely throughout the trial.
Why This Pairing Makes Scientific Sense
These two drugs attack advanced kidney cancer through entirely separate, complementary pathways:
- Axitinib weakens tumors by cutting off their nutrient supply, slowing growth and making cancer cells more vulnerable to immune attack.
- Envafolimab removes the tumor’s immune camouflage, letting the body’s own defense system finish off weakened cancer cells.
Used alone, each drug can slow kidney cancer, but together they create a synergistic effect—meaning their combined power exceeds the sum of each drug working independently. This trial aims to prove that this combination delivers stronger, longer-lasting tumor control as the very first treatment patients receive after an advanced ccRCC diagnosis.
Overview of Clinical Trial : Core Design & Goals
This study is sponsored and run entirely by Peking Union Medical College Hospital, a top-tier academic medical center in China, classified as a single-center, single-arm Phase II prospective clinical trial. We will translate these clinical labels into plain language for everyday readers, skipping overly granular technical details to keep the focus on patient experience and research purpose.
Trial Timeline Estimates
Per official trial documentation, the study was scheduled to open for participant screening starting September 1, 2025, though as of the latest update, recruitment has not yet begun. Researchers plan to finish collecting primary data by February 20, 2027, and fully wrap up all study follow-up by July 20, 2027. At the time of writing, no clinical results have been collected, so all findings from this trial remain pending.
Who Can Join the Trial? Eligibility Rules Translated for Patients & Families
Clinical trials set strict inclusion and exclusion criteria to create a consistent, uniform group of participants so researchers can draw reliable conclusions about the treatment’s effects. Below we simplify the entry rules, separating requirements that qualify patients (inclusion criteria) and factors that disqualify patients (exclusion criteria), removing dense lab value jargon where possible while retaining critical information for anyone considering participation.
Inclusion Criteria: What Makes You Eligible
To sign up for this trial, a patient must meet every one of these requirements:
- Voluntarily sign a formal written informed consent form after fully reviewing all trial risks, benefits, and procedures with the research team.
- Age between 18 and 75 years old, covering adult and older adult patient populations.
- Confirmed diagnosis of unresectable or metastatic clear cell renal cell carcinoma, with no prior systemic anti-cancer treatment of any kind. This means no chemotherapy, immunotherapy, targeted pills, or experimental IV cancer drugs before joining the trial—this combination is strictly for first-line use.
- Scannable, measurable tumors visible on CT or MRI imaging following global RECIST v1.1 guidelines, so doctors can accurately track tumor size changes over time.
- Good baseline physical function: ECOG performance status 0 or 1. Status 0 means patients are fully active with no physical limitations; status 1 means patients cannot perform heavy physical labor but remain mobile and capable of light daily chores and self-care. Patients who are bedridden or reliant on constant assistance cannot join.
- Healthy baseline organ function: Blood tests must show adequate bone marrow, liver, kidney, and blood clotting performance. For patients with mild liver abnormalities, stable lab results after one week of standard liver-protective medication still qualify.
- Doctors estimate the patient has a minimum six-month life expectancy at screening, ensuring participants can complete core early follow-up scans.
- Willingness to attend all scheduled hospital visits, complete imaging scans, blood draws, symptom surveys, and adhere strictly to the prescribed drug schedule. What Participation in This Trial Would Look Like for a Patient
We will outline the general participant journey in simple terms, without overloading readers with minute-by-minute hospital procedures. Anyone who meets eligibility criteria will first move through a screening phase: a series of blood tests, full-body tumor scans, heart function checks, and medical history interviews to confirm they satisfy all inclusion rules and have no disqualifying conditions. If screening passes, patients sign consent and begin the two-drug treatment regimen.
Patients self-administer oral axitinib twice daily at home, with regular reminder check-ins from the research nursing team. They return to Peking Union Medical College Hospital once every three weeks for their subcutaneous envafolimab injection, combined with routine lab blood draws to monitor organ health and blood cell counts. Every 12 weeks, participants complete full CT or MRI scans to measure tumor size per RECIST imaging standards, which feed into the ORR, DCR, PFS, and OS outcome tracking.
Throughout the entire treatment period, patients report all new aches, pains, or unusual symptoms to the study team, who grade every side effect on the standardized CTCAE 5.0 safety scale. Mild side effects may be managed with supportive medications; moderate or severe toxicities could lead to temporary drug pauses, dose adjustments, or permanent treatment discontinuation if the side effect becomes intolerable. At each six-month milestone (6, 12, 18, 24 months), patients fill out quality-of-life PRO questionnaires to capture how treatment impacts daily mood, energy, and physical ability.
Treatment stops for three possible reasons: the cancer progresses and spreads, side effects become unmanageable, or participants hit the maximum 24-month treatment cap. Even after stopping the study drugs, patients continue scheduled follow-up visits for long-term survival and safety tracking to complete the full trial data collection cycle.
Why This Trial Matters for Kidney Cancer Patients Everywhere
For patients newly diagnosed with advanced clear cell kidney cancer, first-line treatment choices shape their entire disease journey. Single-agent targeted pills or standalone immunotherapy work for some, but many patients face limited tumor shrinkage or early disease progression. This envafolimab plus axitinib trial fills a critical gap in global kidney cancer research by testing a convenient subcutaneous immunotherapy paired with an oral targeted drug as an upfront combination regimen.
Several unique strengths set this study apart from other RCC combination trials:
- Subcutaneous immunotherapy delivery: Most PD-L1/PD-1 inhibitors used in kidney cancer require lengthy IV infusions. Envafolimab’s shot format reduces hospital time, lowers stress for anxious patients, and improves long-term treatment adherence.
- Treatment-naive patient population: The trial focuses exclusively on people receiving their first systemic cancer therapy, the group where effective frontline regimens deliver the greatest long-term survival benefits.
- Dual focus on tumor response and quality of life: Beyond measuring tumor shrinkage and survival numbers, researchers track patient-reported daily function—a factor often overlooked in early Phase II trials but vital for patients weighing treatment tradeoffs.
- Real-world safety data collection: The single-center design lets the research team closely monitor every participant’s side effects in a controlled academic hospital environment, generating detailed safety data for future larger multi-center trials.
If the trial delivers positive results—meaning a strong objective response rate, durable progression-free survival, and a manageable safety profile—this envafolimab/axitinib combination will move forward to larger Phase III comparative trials against standard global first-line kidney cancer regimens. Over time, this dual therapy could become a new standard frontline option for advanced clear cell RCC patients worldwide, especially those who prefer the convenience of subcutaneous injections over IV infusions. Even if the results are mixed or show limited benefit, the data will still teach oncologists valuable lessons about how PD-L1 blockade and VEGF inhibition interact in treatment-naive kidney tumors, guiding future drug combination development.
Conclusion: Hope for Improved First-Line Kidney Cancer Care
Advanced clear cell renal cell carcinoma remains a complex, life-altering diagnosis for thousands of people annually, but clinical trials like represent steady progress toward safer, more effective treatment options. By pairing envafolimab, an immune checkpoint injection that disables cancer’s invisibility cloak, with axitinib, an oral targeted pill that starves tumors of their blood supply, researchers at Peking Union Medical College Hospital are testing a synergistic two-pronged therapy for patients who have never received systemic anti-cancer treatment before.
This Phase II single-arm trial will enroll 30 eligible participants to measure tumor shrinkage rates, cancer control duration, long-term survival, treatment safety, and patient quality of life across a maximum two-year treatment window. Strict entry criteria ensure consistent study participants, while comprehensive imaging and lab monitoring capture reliable data on the combination’s strengths and limitations.
For patients, families, and general readers following kidney cancer research, this trial underscores a core truth of modern oncology: combining drugs that attack cancer through separate biological pathways is one of the most promising paths to beating hard-to-treat advanced malignancies. While final study results will not be available until late 2027, the launch of this research brings new hope that a more convenient, potent first-line combination therapy may soon become widely accessible for people living with metastatic or unresectable kidney cancer. Anyone interested in learning more about potential trial participation can contact lead investigator Dr. Weifeng Xu via the phone number or email address listed in the official trial registry documentation.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoRelated Clinical Trials
The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.
The goal of this clinical trial is to learn if the timing of treatments plays a role in how effective the standard-of-care drugs nivolumab/ipilimumab (ICI/ICI) works to treat adults with advanced kidney cancer. The trial will also learn if time-of-day reduces ICI/ICI side-effects. Researchers will compare ICI/ICI given in the morning (before 11:30am) vs in the afternoon (after 1:30pm), to see if circadian rhythm effects how ICI/ICI works to treat advanced kidney cancer. Participants will be randomized in Arm A or Arm B to receive drugs ICI/ICI either in the morning (Arm A) or afternoon (Arm B) as part of their standard-of-care treatment for advanced kidney cancer. Participants will: * Visit the clinic either in the morning (Arm A) or afternoon (Arm B) to receive ICI/ICI treatment as part of their regular medical care for advanced kidney cancer * Frequency of visits will follow standard-of-care guidelines
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoA Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
To find out if the combination of HC-7366 and nivolumab (with or without ipilimumab) can help to control ccRCC. The
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoPhase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
Multicenter Phase 3 study of 177Lu-TLX250 in adult participants with CAIX-expressing advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC). Part 1 will evaluate two dosing regimens to determine the recommended Phase 3 dose (RP3D). Part 2 will compare 177Lu-TLX250 with investigator’s choice of monotherapy aligned with Australian standard-of-care.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoA Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
The goal of this research study is to evaluate how well and safely the study drugs sasanlimab, palbociclib, and axitinib work for treatment of participants with advanced clear cell renal cell carcinoma (ccRCC) or translocation renal cell carcinoma (tRCC). The name of the study drugs involved in this research study is: * Sasanlimab (a type of monoclonal antibody) * Palbociclib (a type of kinase inhibitor) * Axitinib (a type of Vascular endothelial growth factor inhibitor)
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoNeoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
This study will evaluate the effect of investigational drugs, pembrolizumab alone or pembrolizumab with lenvatinib, on the immune systems response to kidney cancer when given before and after surgery to remove kidney cancer.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoInvestigation of Differential Biology of Benign and Malignant Renal Masses Using Advanced Magnetic Resonance Imaging Techniques
The aim of this study is to develop techniques for non-invasive imaging of biology in participants with benign or malignant renal masses based on the novel scanning MRI techniques, including recently invented Hyperpolarised MRI, deuterium metabolic imaging and sodium MRI. This imaging study will: 1) acquire imaging data from human tissues following the injection of hyperpolarised 13C pyruvate and use 13C-MRI to monitor changes in the ratio of 13C-lactate to 13C-pyruvate; 2) acquire imaging data from human tissues using Sodium MRI or 3) acquire imaging data from human tissues following the oral consumable of deuterated glucose. Data acquired during this physiological study will be used to optimise future imaging protocols.In the UK and possibly in other countries, there are some patients with renal masses that are over treated or undergo unnecessary procedures such as surgery or biopsies, as they are thought to have a malignant tumour or a more aggressive tumour but after the procedure it is found that the mass was benign. The aim of this study is to determine whether one or all of these imaging techniques can differentiate between benign and malignant renal masses with the view to developing the techniques further and hopefully reducing the need for over treatment or unnecessary procedures in patients with benign masses.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoCabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma
The goal of the study is to describe real-life use and exposition to nivolumab-cabozantinib among older patients with metastatic clear-cell renal cell cancer
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoIparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Through the combination of aparolitovorelli monoclonal antibody and lenvatinib neoadjuvant therapy, partial nephrectomy can be successfully and safely performed in patients with localized renal cell carcinoma (T1N0M0 or T2N0M0) who have indications for kidney preservation surgery but have difficulty in preserving the kidney (R.E.N.A.L. score \>= 10).
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoPrehabilitation Prior to Surgery for Kidney Tumors
The goal of this clinical trial is to examine if one month of general health optimization before surgery for kidney tumors can help participants recover more quickly from surgery. The optimization process is called prehabiliation, and will last one month. It consists of 1. A comprehensive health assessment 2. Assisted smoking cessation 3. A home exercise program. The investigators will compare an intervention group receiving one month of prehabilitation with a control group receiving the standard of care. Some of the main questions the investigators want to answer are * Are participants in the intervention group more satisfied with their quality of recovery after surgery? * Do participants in the intervention group maintain more of their physical abilites compared to the control group?
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoCD70-targeted immunoPET Imaging of Kidney Cancer
The aim of this study is to establish and optimize the \[18F\]RCCB6 PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agent in renal cancer (especially clear cell renal cell carcinoma) wil be evaluated.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoFasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma
This study is testing whether adding a 5-day fasting-mimicking diet (FMD) can help people with advanced kidney cancer when given together with standard first-line cancer medicines.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoTesting of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Bevacizumab is in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumors. This may slow the growth and spread of tumors. Erlotinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein called EGFR that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Combination therapy with bevacizumab, erlotinib, and atezolizumab may stabilize or shrink advanced hereditary leiomyomatosis and kidney cancer.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoInvestigation of Lymph Node Biology in Kidney Cancer
The purpose of this pilot study is to investigate the phenotype, anti-tumor effector functions, and TCR repertoire of T cells isolated from patient tumor draining lymph nodes (TDLNs) to understand T cell priming and trafficking patterns in Renal Cell Carcinoma (RCC). Data and biospecimen collected will be used for current and future research projects involving the study of kidney cancer biology and related medical conditions. Investigators will use this valuable resource to ask clinically relevant translational questions that pertain to biomarker discovery/validation, identification of novel therapeutic targets, and to better understand the genetic and biological basis of the various kidney cancers.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoProteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
Based on different subtypes, subjects will be placed in one of three treatment groups to explore individual efficacy and safety of various treatment regimen.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoClinical Trial Addressing the Best Surgical Approach for Partial Nephrectomy With Single Port Robotic System in the Management of Localized Renal Cell Carcinoma
This study aims to find out which surgical position is safer and works better for patients candidate to robot-assisted partial nephrectomy (RAPN) – a minimally invasive procedure to remove a small kidney tumor while preserving healthy kidney tissue. During this operation, the patient can be placed in two different positions: * the standard flank position, where the patient lies on their side * a newer supine position, where the patient lies on their back using a technique called Supine Anterior Retroperitoneal Approach (SARA). Both approaches are performed using the Da Vinci® Single Port (SP) robotic system, a state-of-the-art surgical robot that allows the operation to be done through a single small incision. The traditional flank position has been used for many years, but it can be uncomfortable for patients and may increase the risk of certain anesthetic or nerve-related complications, especially in people with higher body weight. The new supine SARA technique could make surgery faster, safer, and less painful, but it has not yet been tested in a randomized study. This is the first clinical trial designed to directly compare these two approaches in patients with small and localized kidney cancers (tumors ≤7 cm, stage cT1). The study will include 124 patients treated at ASST Grande Ospedale Metropolitano Niguarda in Milan, Italy – a leading center in robotic urologic surgery.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoAn Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
This phase II trial compares the safety and effectiveness of 89Zr-DFO-GmAb positron emission tomography (PET)/computed tomography (CT) compared to contrast-enhanced CT after surgery in detecting clear cell renal cell cancer that has come back (recurrent). For some patients, the risk of recurrence after surgery remains high. Conventional CT methods, such as contrast-enhanced CT, may not detect small volume or micrometastatic disease. PET/CT with radiotracers, such as 89Zr-DFO-GmAb, may improve detection of tumor cells. Girentuximab (GmAb), a monoclonal antibody, is tagged with zirconium-89, a radioactive atom (which is also known as an isotope). The zirconium-89 (89Zr) isotope is attached to girentuximab with desferrioxamine (DFO) and this combined product is called 89Zr-DFO-girentuximab. 89Zr-DFO-girentuximab attaches itself to a protein on the surface of clear cell renal cell tumor cells called CAIX. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 89Zr-DFO-GmAb. Because some cancers, including clear cell renal cell cancer, take up 89Zr-DFO-GmAb it can be seen with PET. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient’s body. Using contrast agents with CT scan to enhance the images (contrast-enhanced CT) is standard of care imaging. 89Zr-DFO-GmAb PET/CT may be safe and effective compared to contrast-enhanced CT in detecting recurrent clear cell renal cell cancer after surgery.
PDF$29 only! Buy Clinical Trial Full Report With Contact Info[18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma
Staging of kidney cancer is primarily achieved by computerized tomography (CT) scans or magnetic resonance imaging (MRI). If a patient is found to have limited metastatic disease, surgical removal or radiation therapy could be considered in order to control the majority of the disease. However, if metastases are more widespread, systemic (drug) therapy may be the preferred management option. The identification of additional metastatic sites using more sensitive imaging modalities therefore has the potential to alter management, and this remains an unmet need in the field. This study will investigate the utility of positron emission tomography (PET) imaging with PSMA (prostate specific membrane antigen). Kidney cancer of the clear cell subtype has demonstrated high expression of PSMA, making it a disease in which PSMA-targeted PET imaging could help to identify occult metastatic disease.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoAutologous Dendritic Cell Vaccine in Kidney Cancer
The purpose of this study is to estimate the probability of immune response for the combination treatment of dendritic cell vaccine with oral cabozantinib and characterize the safety profile of interventional therapy.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoCD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors
This study is for patients who have a type of cancer that expresses the protein CD70, which includes lymphoma (lymph gland cancer), myeloma and solid tumors including some sarcomas and kidney cancers, and the cancer has come back or has not gone away after standard of care treatment. As there are limited or no remaining standard treatments available to treat this cancer, patients are being asked to volunteer to be in a gene transfer research study using special immune cells to create a specialized immune cell that will recognize a protein called CD70 that is expressed on the outside surface of the tumor cells in the body. This research study combines different ways of fighting disease by using T cells and “arming” them to recognize a specific protein on cancer cells. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells including tumor cells. T cells by themselves have been used to treat patients with cancers and have shown promise, but have not been strong enough to cure most patients. The protein used in this study is called anti-CD70. It has been developed from human CD27 on normal T cells, since it is the natural binding partner that can connect with CD70. This anti-CD70 protein sticks to tumor cells when it binds to CD70. CD70 binders have been used to treat people with different types of cancers. For this study, anti-CD70 has been changed so that instead of floating free in the blood it is now joined to the T cells. When binder is joined to a T cell in this way it is called a chimeric receptor or “CAR T cell”. The doctors then made another change to cause these T cells to kill any cell that has CD70. This causes the “CAR T cells” to kill blood cancer cells which are confirmed to have CD70. In the laboratory, investigators have found that T cells work better if there are proteins added that stimulate T cells. The anti-CD70 (CD27) protein is unique because it can bind to CD70 on tumor cells but also stimulates the T cells that express it. Adding the CD27 makes the cells grow better and may help them to last longer in the body, thus giving the cells a better chance of killing the tumor cells. These CD70 “CAR” T cells are investigational products not approved by the Food and Drug Administration. The purpose of this study is to find a dose of CAR T cells that is safe, to learn what the side effects are and to see whether this therapy might help people with lymphoma (lymph gland cancer), myeloma and certain solid tumors including some sarcomas and kidney cancers.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoA Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
This Phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 in combination with tyrosine kinase inhibitor (TKI) with or without pembrolizumab (BL-B01D1+TKI±Pembrolizumab) in patients with locally advanced or metastatic renal cancer.
PDF$29 only! Buy Clinical Trial Full Report With Contact Info